Recce Pharmaceuticals Secures Japan Patent for RECCE Anti-Infectives

Recce Pharmaceuticals Limited (ASX: RCE) has received a notice of allowance from the Japan Patent Office for Patent Family 4, securing protection until 2041 for its RECCE® anti-infectives, R327 and R529. The patent covers the preparation process, treatment applications for bacterial and viral infections—including ABSSSI, diabetic foot infections, pneumonia, UTIs, gonorrhea, influenza, and SARS-CoV-2—and various administration methods, including oral, inhalation, and topical applications. Japan, the world’s third-largest pharmaceutical market, presents significant opportunities, with its antibiotic resistance market projected to reach AU$411.3 million by 2030. This marks the fourth Family 4 patent granted, alongside approvals in Australia, Canada, and Israel, with further PCT submissions underway. CEO James Graham emphasized that global patent protection reinforces Recce’s commitment to addressing unmet medical needs with innovative anti-infective solutions, positioning the company for impactful contributions to global healthcare.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com